H.C. Wainwright Starts Lipocine Inc (LPCN) at Buy, PT $25

H.C. Wainwright initiated coverage on Lipocine Inc (NASDAQ: LPCN) with a Buy rating and a price target of $25.

Analyst Corey Davis said, "Our Lipocine investment thesis hinges on the success of three late-stage orally-formulated steroid products to better compete with current products that are either injectable or topical. LPCN 1021 (brand name Tylando) is a twice-daily oral formulation of testosterone for hypogonadal men (low testosterone), that received a Complete Response Letter on June 29, 2016 and should have clarity as to the path forward this month. LPCN 1111 is a once-daily next generation prodrug of testosterone that announced successful Phase 2b on September 26. LPCN 1107 is an oral version of hydroxyprogesterone for pre-term birth that would compete directly with Makena and is ready to enter Phase 3."

For an analyst ratings summary and ratings history on Lipocine Inc click here. For more ratings news on Lipocine Inc click here.

Shares of Lipocine Inc closed at $4.17 yesterday.

You May Also Be Interested In

• Equirus Starts JSW Energy Ltd (JSW:IN) at Long (1)
• Life Insurance Corporation (LICI:IN) PT Raised to INR1,280 at ICICI Securities
• Indian Bank (INBK:IN) PT Raised to INR970 at Axis Capital Limited